S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
NCT03091660
Active Not Recruiting
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from retu... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/27/2025
Locations: University of South Alabama Mitchell Cancer Institute, Mobile, Alabama +173 locations
Conditions: Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Register for Updates
Entre Herman@s: Promoting Health Among Latino MSM
NCT05805306
Active Not Recruiting
This is a randomized controlled trial with an attention placebo control group. The goal of this study is to decrease HIV incidence in Latino men who have sex with men by engaging their siblings in PrEP-use promotion. In the intervention arm, siblings will be trained to engage their gay brother in PrEP conversations. In the control arm, siblings will be trained to engage their gay brother in conversations about vaccines to prevent COVID, Hepatitis A/B, or MPOX.
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
03/25/2025
Locations: Charles R. Drew University of Medicine and Science, Los Angeles, California
Conditions: HIV Infections
Register for Updates
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
NCT05672927
Recruiting
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
Gender:
FEMALE
Ages:
Between 27 years and 45 years
Trial Updated:
03/25/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Immunization, HPV Infection, Human Papillomavirus
Register for Updates
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824194
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatr... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
03/25/2025
Locations: Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400013, Birmingham, Alabama +23 locations
Conditions: Pneumococcal Immunization
Register for Updates
Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
NCT06038617
Recruiting
This is a prospective, randomized, open-label clinical trial to evaluate the safety of COVID-19 vaccination and other routine childhood vaccines given simultaneously at Visit 1, as compared to sequential vaccination of COVID-19 vaccine and other vaccines at separate visits (Visits 1 and 2).
Gender:
ALL
Ages:
Between 6 months and 4 years
Trial Updated:
03/24/2025
Locations: Kaiser Permanente Northern California, Oakland, California +4 locations
Conditions: Fever After Vaccination, Fever, Seizures Fever
Register for Updates
Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas
NCT03334305
Terminated
It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells are not stimulated enough to kill the tumor. In this research study, we will use a patient's tumor to make a vaccine which we hope will stimulate T-cells to kill tumor cells and leave normal cells alone. High grade glio... Read More
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
03/24/2025
Locations: Children's of Alabama at UAB, Birmingham, Alabama +2 locations
Conditions: Malignant Glioma, High Grade Glioma
Register for Updates
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
NCT06015308
Recruiting
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD). The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis \[Tdap\]) and Pneumovax 23 (PPSV) vaccines in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Clinical Research Center of Alabama - Homewood- Site Number : 8401101, Birmingham, Alabama +56 locations
Conditions: Dermatitis Atopic
Register for Updates
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
NCT05947071
Recruiting
Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two strategies to overcome poor immune responses in SOT recipients: (1) administration of high-dose (HD)-IIV compared to SD-IIV and (2) two doses of SD-IIV compared to one dose of SD-IIV in the same influenza season. One study compared HD-IIV vs. SD-IIV in adult SOT rec... Read More
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
03/20/2025
Locations: Stanford University, Stanford, California +7 locations
Conditions: Immunization; Infection, Transplantation Infection, Influenza
Register for Updates
Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)
NCT03396575
Terminated
The standard of care for children with DIPG includes focal radiotherapy (RT) but outcomes have remained dismal despite this treatment. The addition of oral Temozolomide (TMZ) concurrently with RT followed by monthly TMZ was also found to be safe but ineffective. Recent studies in adults have shown that certain types of chemotherapy induce a profound but transient lymphopenia (low blood lymphocytes) and vaccinating and/or the adoptive transfer of tumor-specific lymphocytes into the cancer patient... Read More
Gender:
ALL
Ages:
Between 3 years and 30 years
Trial Updated:
03/20/2025
Locations: UF Health Shands Children's Hospital, Gainesville, Florida
Conditions: Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Register for Updates
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
NCT06686654
Recruiting
The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation (hereafter referred to as hMPV/RSV vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by hMPV and/or RSV among adults aged 60 years and older. Overall, the study is designed to address the following goals: * Assess the safety profile of the candidate... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/19/2025
Locations: CenExel CNS-Garden Grove- Site Number : 8400017, Garden Grove, California +18 locations
Conditions: Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Register for Updates
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
NCT06864143
Recruiting
The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/19/2025
Locations: Headlands Research Scottsdale, Scottsdale, Arizona +16 locations
Conditions: Influenza, SARS-CoV-2
Register for Updates
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
NCT03384914
Active Not Recruiting
The main purpose of this study is to evaluate the safety of each study vaccine and to evaluate the effect on the time to disease recurrence (assessed by disease free survival). Participants will be assigned to receive one of two study vaccines (DC1 study vaccine vs. WOKVAC). The study vaccine will be administered in two phases: a study vaccination phase and a booster phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida +6 locations
Conditions: Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
Register for Updates